GlobeNewswire (Aug 8, 2014)
GlobeNewswire (Aug 5, 2014)
GlobeNewswire (Jul 25, 2014)
MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical DevelopmentGlobeNewswire (Jul 23, 2014)
GlobeNewswire (Jul 4, 2014)
GlobeNewswire (Jun 17, 2014)
We currently have no Breaking News on this stock.
There are no StockTalks on this stock yet.
GLPYY vs. ETF Alternatives
Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that... More
Other News & PR